TY - CHAP M1 - Book, Section TI - Chapter 46. Sepsis with Acute Organ Dysfunction A1 - Ely, E. Wesley A1 - Goyette, Richert E. A2 - Hall, Jesse B. A2 - Schmidt, Gregory A. A2 - Wood, Lawrence D.H. PY - 2005 T2 - Principles of Critical Care, 3e AB - Sepsis is the combination of a known or suspected infection and an accompanying systemic inflammatory response.Severe sepsis is sepsis with acute dysfunction of one or more organ systems; septic shock is a subset of severe sepsis.Severe sepsis is common, frequently fatal, and expensive. More than 750,000 cases occur annually in the United States.Effective management of patients with severe sepsis requires early identification, cardiopulmonary support, antibiotics, source control, and general supportive care.The prognosis of the patient with severe sepsis is related to the number of dysfunctional organs.Cardiopulmonary support consists of early and aggressive fluid resuscitation, maintenance of mean arterial pressure at 65 mm Hg or higher, and measures to maximize and maintain tissue oxygenation; judging the adequacy of tissue oxygenation is informed by measurement of the mixed venous oxygen saturation, and supportive therapy is most effective and beneficial when provided in the first hours of presentation.Patients should receive early intravenous empirical antibiotics directed at all possible sources of infection. Appropriate antibiotics decrease the mortality rate by 10% to 15% in patients with severe sepsis.Source control can be surgical or nonsurgical and is intended to remove or lessen the burden from the primary focus of infection.Despite appropriate antibiotics, source control, and organ support, the mortality rate in patients with severe sepsis remains at 28% to 50%.Specific antisepsis interventions have recently been introduced that target multiple pathophysiologic aspects of the sepsis cascade and can improve outcomes.To maximize outcomes, supportive measures must be introduced to ensure proper nutrition; maintain fluid, glucose, and electrolyte homeostasis; promote tissue oxygenation; and prevent complications. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2022/05/28 UR - accessanesthesiology.mhmedical.com/content.aspx?aid=2290047 ER -